|
|
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens |
| 1 R01 AG065805-01A1 |
BRESS, ADAM P |
NIA |
2020 |
|
|
R01 Upstream Approaches to Improve Late Life Care for People Living with Dementia |
| 1 R01 AG066139-01A1 |
JARRÍN MONTANER, OLGA F |
NIA |
2020 |
|
|
Complexity of FMRI in Alzheimers Disease |
| 1 R01 AG066711-01 |
JANN, KAY |
NIA |
2020 |
|
|
Dietary patterns and hearing loss in middle aged and older Americans |
| 1 R03 AG065861-01A1 |
TALEGAWKAR, SAMEERA A |
NIA |
2020 |
|
|
HFE SNP Effect on Alzheimers Regional Brain Susceptibility |
| 1 R21 AG064486-01A1 |
CONNOR, JAMES ROBERT |
NIA |
2020 |
|
|
Developing a Univariate Neurodegeneration Imaging Biomarker with Optimal Transportation |
| 1 R21 AG065942-01A1 |
WANG, YALIN |
NIA |
2020 |
|
|
Skeletal muscle extracellular vesicle signaling in Alzheimers Disease prevention |
| 1 R21 AG066488-01 |
GEIGER, PAIGE C |
NIA |
2020 |
|
|
Characterization of amyloid-B:a7B2-nicotinic acetylcholine receptor interactions relevant to Alzheimers disease |
| 1 R21 AG067029-01 |
LUKAS, RONALD J |
NIA |
2020 |
|
|
Are the impairments of arginine metabolism as found in Alzheimers disease also present in patients developing post-operative delirium and cognitive decline? |
| 1 R21 AG067083-01 |
GRAHAM, STEWART F |
NIA |
2020 |
|
|
C. Elegans as a Model of Cell Senescence and Alzheimers Disease |
| 1 R21 AG067147-01 |
JOHNSON, THOMAS E |
NIA |
2020 |
